Skip to main content
. 2019 Mar 8;98(10):e14568. doi: 10.1097/MD.0000000000014568

Figure 2.

Figure 2

Impact of BIM deletion polymorphism on response to EGFR-TKIs. (A) Odds ratio (OR) for objective response rate (ORR) to EGFR-TKIs in NSCLC patients with BIM deletion polymorphism versus those with BIM wild. (B) OR for disease control rate (DCR) to EGFR-TKI in NSCLC patients with BIM deletion polymorphism versus those with BIM wild. (C) Funnel plot of ORR analysis. (D) Funnel plot of DCR analysis. BIM = B cell lymphoma-2-like 11, EGFR-TKIs = epidermal growth factor receptor-tyrosine kinase inhibitors, NSCLC = nonsmall cell lung cancer.